Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference
10 janv. 2025 08h00 HE
|
Recludix Pharma, Inc.
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D.,...
Recludix Pharma to Participate in Two Investor Conferences in December
25 nov. 2024 08h00 HE
|
Recludix Pharma, Inc.
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in discovery of inhibitors of challenging targets for inflammatory disease, today announced that members of Recludix’s...
Recludix Pharma to Present Data Demonstrating its Oral STAT3 Inhibitor has Differentiated Efficacy and Safety as Compared to JAK/TYK2 Inhibition in In Vivo Models of Inflammatory Arthritis
14 nov. 2024 10h00 HE
|
Recludix Pharma, Inc.
-REX-7117 is an oral, potent and selective STAT3 SH2 domain inhibitor, which demonstrated strong efficacy in an in vivo model of inflammatory arthritis -STAT3 inhibition does not impair the...
Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024
05 août 2024 06h05 HE
|
Recludix Pharma, Inc.
SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in discovery of inhibitors of challenging targets for inflammatory disease and cancer, today announced that Fierce Biotech has...
Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and Safety in Preclinical Models of Th17 Mediated Skin Inflammation in Oral Plenary Session at SID Annual Meeting
17 mai 2024 15h00 HE
|
Recludix Pharma, Inc.
-- In a preclinical model of psoriasis, the efficacy of oral small molecule REX-7117 was comparable to an anti-IL-17A biologic SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader...
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian Ray
23 avr. 2024 08h00 HE
|
Recludix Pharma, Inc.
Newly appointed head of R&D, Dr. Nirula, joins Recludix from Eli Lilly with over two decades of clinical development experience SAB member, Dr. Ray, has over two decades of experience in...
Recludix Pharma to Participate in Two Investor Conferences in March
28 févr. 2024 08h00 HE
|
Recludix Pharma, Inc.
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
Recludix Pharma to Present at Two Investor Conferences in February
06 févr. 2024 08h00 HE
|
Recludix Pharma, Inc.
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
Recludix Pharma to Present at Two Investor Conferences in November
09 nov. 2023 08h00 HE
|
Recludix Pharma, Inc.
SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
Recludix Pharma Presents Preclinical Data Demonstrating Strong Efficacy and Favorable Safety Profile of REX-7117 Versus TYK2 and JAK Inhibitors at the Dermatology Drug Development Summit
31 oct. 2023 16h00 HE
|
Recludix Pharma, Inc.
- REX-7117 found to have superior efficacy to a clinically-relevant dose of deucravacitinib in a preclinical model of psoriasis - REX-7117, as a highly selective STAT3 inhibitor, demonstrates...